Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
P/S ratio for Anavex Life Sciences Corp. (AVXL)
P/S ratio as of 2023: 0.00
According to Anavex Life Sciences Corp.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2022 the company had a P/S ratio of 0.00.
P/S ratio history for Anavex Life Sciences Corp. from 2004 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 0.00 |
| 2022 | 0.00 |
| 2021 | 0.00 |
| 2020 | 0.00 |
| 2019 | 0.00 |
| 2018 | 0.00 |
| 2017 | 0.00 |
| 2016 | 0.00 |
| 2015 | 0.00 |
| 2014 | 0.00 |
| 2013 | 0.00 |
| 2012 | 0.00 |
| 2011 | 0.00 |
| 2010 | 0.00 |
| 2009 | 0.00 |
| 2008 | 0.00 |
| 2007 | 0.00 |
| 2006 | 0.00 |
| 2005 | 0.00 |
| 2004 | 0.00 |